Prognostic Value of Normal Exercise and Adenosine 99mTc-tetrofosmin SPECT Imaging:
Results From the Multicenter Registry of 4,728 Patients
L.J. Shaw, R. Hendel,
S. Borges-Neto, M.S. Lauer, N. Alazaki, J. Burnette, E. Krawczynska,
M. Cerqueira, and J. Maddahi; for the MYOVIEW Multicenter Registry
Reliable Prognosis Associated With Normal Exercise and Adenosine
Stress SPECT Imaging Studies
- The favorable prognosis of patients with a normal stress
scintigraphic study using a Tc99m agent is well documented1-3
- MYOVIEW™ (technetium Tc99m tetrofosmin)
has recently been evaluated for its risk stratification and prognostic
capabilities in patients at varying risk for cardiovascular events4
Shaw Multicenter Trial Reports Excellent Prognostic Value Associated
With a Normal MYOVIEW SPECT Scan4
- Shaw and cohorts evaluated the prognostic merit of
MYOVIEW SPECT imaging in a multicenter registry trial of 4,728 cardiac
patients in five hospitals4
- For patients undergoing stress SPECT imaging, a low-risk
MYOVIEW scan was associated with an annualized cardiac death rate of
0.6%,4 according to the Shaw study
- For purposes of risk assessment, low risk
is defined as <1% cardiac mortality rate per year5
Clinical Value of the Normal Scan Is Not Radiopharmaceutical Dependent
- Various studies, including the recent Shaw trial, provide
evidence that the excellent prognosis associated with a normal SPECT
scan is not radiopharmaceutical dependent1-4
- When comparing prior published outcomes of SPECT imaging
with the Shaw trial, the overall survival rates were similar and ranged
from 99.3% to 99.7%1-4
- According to the Shaw Study, annualized cardiac survival
rates did not significantly differ between MYOVIEW and other agents4
The
Shaw multicenter registry trial revealed similar overall survival rates
in MYOVIEW patients and in patients from published studies of other perfusion
agents, with rates ranging from 99.3% to 99.7%.
References:
1. Iskander S, Iskandrian AE. Risk assessment using single-photon emission
computed tomographic technetium-99m sestamibi imaging. J Am Coll Cardiol.
1998;32:57-62.
2. Gibbons RJ, Hodge DO, Berman DS, et al. Long-term outcome of patients with
intermediate-risk exercise electrocardiograms who do not have myocardial perfusion
defects on radionuclide imaging. Circulation. 1999;100:2140-2145.
3. Shaw LJ, Hachamovitch R, Heller GV, et al. Noninvasive strategies for the
estimation of cardiac risk in stable chest pain patients. The Economics of
Noninvasive Diagnosis (END) Study Group. Am J Cardiol. 2000;86:1-7.
4. Shaw LJ, Hendel R, Borges-Neto S, et al, for the Myoview Multicenter Registry.
Prognostic value of normal exercise and adenosine 99mTc-tetrofosmin SPECT imaging:
results from the multicenter registry of 4,728 patients. J Nucl Med. 2003;44:1-6.
5. Berman DS, Shaw LJ, Germano G, Fuster V, Alexander RW, O’Rourke
RA, eds. Hurst’s The Heart. 10th ed. The McGraw-Hill Co., New York, NY: 2001;16:525-565.
|
|
)
)